Clinical Scorecard: A recombinant IgG1 Fc-domain protein reduces inflammation in demyelinating peripheral neuropathy
At a Glance
Category
Detail
Condition
Key Mechanisms
T cell– and/or autoantibody-driven injury to peripheral nerves; engagement of type II Fc receptors promoting anti-inflammatory signaling, particularly through Treg expansion.
Target Population
Care Setting
Key Highlights
NVG-2089 demonstrated neuroprotective efficacy comparable to IVIg, with specific mechanisms involving Treg expansion.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Monitor for treatment-related complications such as headache, aseptic meningitis, renal dysfunction, and thromboembolic complications, along with neurological recovery.
Risks
Patient & Prescribing Data
Patients with GBS and CIDP, particularly those experiencing limitations with IVIg.
NVG-2089 offers a dose-efficient alternative to IVIg.
Clinical Best Practices
Consider NVG-2089 for patients requiring lower dosing alternatives to IVIg, and utilize immunophenotyping to assess Treg expansion in treatment response, particularly in the context of monitoring efficacy.
